Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 7
Submit an article Journal homepage
3,934
Views
23
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis

Chul Won JungSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaCorrespondence[email protected]
,
Lee-Yung ShihChang Gung Memorial Hospital-LK and Chang Gung University, Chang Gung, Taiwan
,
Zhijian XiaoInstitute of Hematology and Blood Diseases Hospital and State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China
,
Jin JieFirst Affiliated Hospital, Zhejiang University College of Medicine, Zhejiang, China
,
Hsin-An HouNational Taiwan University Hospital, Taipei, Taiwan
,
Xin DuGuangdong General Hospital, Guangdong, China
,
Ming-Chung WangChang Gung Memorial Hospital-KS, Kaohsiung, Taiwan
,
Seonyang ParkSeoul National University Hospital, Seoul, Korea
,
Ki-Seong EomSeoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea
,
Kenji OritaniOsaka University Hospital, Osaka, Japan
,
Shinichiro OkamotoKeio University Hospital, Tokyo, Japan
,
Tetsuzo TauchiTokyo Medical University Hospital, Tokyo, Japan
,
Jin Seok KimYonsei University College of Medicine, Severance Hospital, Seoul, Korea
,
Daobin ZhouPeking Union Medical College Hospital, Beijing, China
,
Shigeki SaitoNagoya University Hospital, Aichi, Japan
,
Junmin LiRuijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
,
Hiroshi HandaGunma University Hospital, Gunma, Japan
,
Li JianyongJiangsu Province Hospital, Nanjing, China
,
Kohshi OhishiMie University Hospital, Mie, Japan
,
Ming HouQilu Hospital, Shandong University, Jinan, China
,
Wu DepeiThe First Affiliated Hospital of Soochow University, Suzhou, China
,
Katsuto TakenakaKyushu University Hospital, Fukuoka, Japan
,
Ting LiuWest China Hospital, Sichuan University, Chengdu, China
,
Yu HuUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
,
Taro AmagasakiNovartis Pharma KK, Tokyo, Japan
,
Kazuo ItoNovartis Pharma KK, Tokyo, Japan
,
Prashanth GopalakrishnaNovartis Pharma AG, Basel, Switzerland
&
Koichi AkashiKyushu University Hospital, Fukuoka, Japan
 show all
Pages 2067-2074 | Received 21 Aug 2014, Accepted 09 Sep 2014, Published online: 20 Nov 2014

References

  • Barosi G, Rosti V, Vannucchi AM. Therapeutic approaches in myelofibrosis. Expert Opin Pharmacother 2011;12:1597–1611.
  • Mesa RA, Green A, Barosi G, et al. MPN-associated myelofibrosis (MPN-MF). Leuk Res 2011;35:12–13.
  • Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007;109:68–76.
  • Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895–2901.
  • Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol 2013;6:79.
  • Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799–807.
  • Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787–798.
  • Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047–4053.
  • Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013;98: 1865–1871.
  • Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Vol 2. Lyon: IARC; 2008.
  • Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
  • Mesa RA, Kantarjian H, Tefferi A, et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement:performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 2011;117:4869–4877.
  • Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009;33:1199–1203.
  • Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117–1127.
  • Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007;110:4030–4036.
  • Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009;114:1477–1483.
  • Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008;112:2726–2732.
  • Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 2008;83:491–497.
  • Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 2009;60:233–245.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.